Your shopping cart is currently empty

Irsenontrine (E2027) is a selective and orally active inhibitor of phosphodiesterase 9 (PDE9), primarily used for researching neurological diseases.


| Description | Irsenontrine (E2027) is a selective and orally active inhibitor of phosphodiesterase 9 (PDE9), primarily used for researching neurological diseases. |
| In vitro | Irsenontrine (E2027) is an orally administered compound that selectively inhibits phosphodiesterase 9 (PDE9), exhibiting targeted activity. |
| In vivo | Irsenontrine, administered orally at doses of 0.3 and 3.3 mg/kg, significantly enhances novel object exploration in scopolamine-induced rats at the 3.3 mg/kg dose. Furthermore, the combined oral administration of Irsenontrine (1 mg/kg) and memantine hydrochloride (1 mg/kg) results in a significantly higher exploration percentage of a novel object compared to the administration of memantine hydrochloride (1 mg/kg) alone. |
| Synonyms | Irsenontrine, E2027 |
| Molecular Weight | 390.443 |
| Formula | C22H22N4O3 |
| Cas No. | 1429509-82-9 |
| Smiles | [H][C@@]1(CCOC1)n1ncc2c1c1ccc(cc1[nH]c2=O)-c1c(C)cnc(OC)c1C |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.